October 25, 2018
The majority shareholders of Medite Cancer Diagnostics Inc. only served one of the company's five board members named in their derivative suit alleging the directors diluted company shares to keep their jobs, indicating their claims are too weak to proceed, the executives argued in their bid to dismiss the suit in California federal court.